Wayne Harris MD
Academic Appointment
- Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- PhD from Loma Linda University, Loma Linda
- MD from Loma Linda University, Loma Linda
- BA from Andrews University, Berrien Springs
Research
Focus
- Cooperative Group Clinical Trials National Principal or Co-Principal Investigator (1) E2810: Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastasectomy (2) E1200: A Randomized Phase II Study of Gemcitabine Plus Radiotherapy vs. Gemcitabine, 5-Fluorouracil and Cisplatin Followed by Radiotherapy and 5-Fluorouracil for Patients Locally Advanced, Potentially Resectable Adeno-carcinoma of the Pancreas
Publications
-
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors.
Volume: 17 Page(s): 17588359251316243
01/01/2025 Authors: Yildirim A; Wei M; Liu Y; Nazha B; Brown JT; Carthon BC; Choi Y; Suh L; Goswamy RV; McClintock GR -
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
Nat Genet Volume: 56 Page(s): 1878 - 1889
09/01/2024 Authors: Skerget S; Penaherrera D; Chari A; Jagannath S; Siegel DS; Vij R; Orloff G; Jakubowiak A; Niesvizky R; Liles D -
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.
J Clin Oncol Volume: 42 Page(s): 2061 - 2070
06/10/2024 Authors: Appleman LJ; Kim SE; Harris WB; Pal SK; Pins MR; Kolesar J; Agarwal N; Parikh RA; Vaena DA; Ryan CW -
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience.
J Immunother Precis Oncol Volume: 5 Page(s): 52 - 57
08/01/2022 Authors: Martini DJ; Olsen TA; Goyal S; Liu Y; Evans ST; Hitron EE; Russler GA; Yantorni L; Caulfield S; Brown JT -
Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials.
Cancers (Basel) Volume: 14
06/10/2022 Authors: Zhuang TZ; Case K; Olsen TA; Brown JT; Carthon BC; Kucuk O; Goldman J; Harris W; Bilen MA; Nazha B -
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
Clin Genitourin Cancer Volume: 20 Page(s): 53 - 59
02/01/2022 Authors: Martini DJ; Evans ST; Liu Y; Shabto JM; Uner OE; Olsen TA; Brown JT; Russler GA; Yantorni L; Caulfield S -
Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy.
Front Endocrinol (Lausanne) Volume: 13 Page(s): 779915
01/01/2022 Authors: Olsen TA; Zhuang TZ; Caulfield S; Martini DJ; Brown JT; Carthon BC; Kucuk O; Harris W; Bilen MA; Nazha B -
Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
Oncologist Volume: 26 Page(s): 1017 - 1025
12/01/2021 Authors: Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L -
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Oncologist Volume: 26 Page(s): e1742 - e1750
10/01/2021 Authors: Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA -
Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
J Immunother Cancer Volume: 9
07/01/2021 Authors: Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS